This proposal outlines experiments to design and test antibodies to Latent TGFβ binding protein. The rationale for developing these antibodies are to determine whether such reagents are useful to limit release of latent TGFβ or other TGFβ family members. The goal is determine whether this step limits pathology in disease states like muscular dystrophy. The aims are to work with a commercial enterprise to develop the antibodies. We will test the antibodies using immunoblotting, immunofluorescence microscopy, immunoprecipitation, and in vitro proteolysis. One lead reagents have been identified, the subsequent goals are to test these reagents in mouse models of muscular dystrophy. Outcome will be determined by measuring in vivo cardiopulmonary and neuromuscular endpoints and ex vivo surrogate markers.
|Effective start/end date||6/7/16 → 3/31/19|
- Solid Biosciences LLC (Agmt 06/07/16)